Angelman syndrome is a rare disease that disrupts the normal development and function of cells, particularly in the nervous system, leading to severe developmental delays and learning disabilities.

Ultragenyx reports early success with Angelman syndrome drug, backing up 2022 acquisition. By Allison DeAngelis April 15, 2024. Reprints. David Goldman/AP.

Sterling has picked The Angelman Syndrome Foundation as his charity choice. If you would like to nominate someone for My Hero, send us an email at myhero@newschannel5.com.

Elk Grove child diagnosed with Angelman Syndrome, family hope for more research 02:00. ELK GROVE - The world turned upside down for an Elk Grove family when their young daughter received a rare ...

--Ultragenyx Pharmaceutical Inc. today announced new data from the Phase 1/ 2 study of GTX-102 for the treatment of Angelman syndrome. These data will be discussed in more detail in a corporate ...

(RTTNews) - Ionis Pharmaceuticals, Inc. (IONS) Thursday reported positive topline data from the HALOS Phase 1/2a study of ION582 in Angelman syndrome, a neurodevelopmental disorder.

Farrell spoke about his 20-year-old son, James, who has a genetic disorder, Angelman syndrome, in an exclusive interview with People Magazine. “Once your child turns 21, they’re kind of on ...